Global cancer drug spending is projected to exceed $400 billion by 2028, up from $252 billion in 2024, with the US accounting for 46%. Recent FDA approvals include daraxonrasib for pancreatic cancer and therapies for breast and colon cancers. Key companies like Oncolytics Biotech and Revolution Medicines are advancing treatments targeting RAS-mutant colorectal and pancreatic cancers, with significant clinical trial data expected soon.
This news item displays a headline only and has no other text.